JP2009511014A5 - - Google Patents

Download PDF

Info

Publication number
JP2009511014A5
JP2009511014A5 JP2008534644A JP2008534644A JP2009511014A5 JP 2009511014 A5 JP2009511014 A5 JP 2009511014A5 JP 2008534644 A JP2008534644 A JP 2008534644A JP 2008534644 A JP2008534644 A JP 2008534644A JP 2009511014 A5 JP2009511014 A5 JP 2009511014A5
Authority
JP
Japan
Prior art keywords
self
vector
enhancer
composition
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008534644A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009511014A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/038776 external-priority patent/WO2007044394A2/en
Publication of JP2009511014A publication Critical patent/JP2009511014A/ja
Publication of JP2009511014A5 publication Critical patent/JP2009511014A5/ja
Pending legal-status Critical Current

Links

JP2008534644A 2005-10-05 2006-10-04 自己免疫疾患の処置のための組成物および方法 Pending JP2009511014A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72420305P 2005-10-05 2005-10-05
PCT/US2006/038776 WO2007044394A2 (en) 2005-10-05 2006-10-04 Compositions and methods for treatment of autoimmune disease

Publications (2)

Publication Number Publication Date
JP2009511014A JP2009511014A (ja) 2009-03-19
JP2009511014A5 true JP2009511014A5 (https=) 2010-12-16

Family

ID=37943343

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008534644A Pending JP2009511014A (ja) 2005-10-05 2006-10-04 自己免疫疾患の処置のための組成物および方法

Country Status (9)

Country Link
US (1) US20100160415A1 (https=)
EP (1) EP1931390B1 (https=)
JP (1) JP2009511014A (https=)
CN (1) CN101365494A (https=)
AU (1) AU2006302477A1 (https=)
CA (1) CA2624615A1 (https=)
IL (1) IL190520A0 (https=)
NZ (1) NZ567150A (https=)
WO (1) WO2007044394A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1668105T3 (pl) * 2003-09-29 2019-03-29 Deb Ip Limited Kompozycje żelopodobne i pieniące o dużej zawartości alkoholu
DE102004062775A1 (de) 2004-12-21 2006-06-29 Stockhausen Gmbh Alkoholischer Pumpschaum
BRPI0608347A2 (pt) 2005-03-07 2009-12-08 Deb Worldwide Healthcare Inc composição alcoólica espumável, concentrado de composição, composição alcoólica desinfetante espumável, métodos para formar, produzir e dispensar uma espuma, dispensador não pressurizado, e, métodos para usar uma composição alcoólica de espuma para desinfecção pessoal e para produzir e aplicar a uma pele de indivìduo uma composição alcoólica de espuma desinfetante de pele
WO2010151420A1 (en) * 2009-06-05 2010-12-29 Bayhill Therapeutics, Inc. Compositions and methods for treatment of insulin-dependent diabetes mellitus
EP2525825A1 (en) * 2010-01-20 2012-11-28 Bayhill Therapeutics, Inc. Combination therapy to treat autoimmune diseases
EP2716756B1 (en) * 2011-05-25 2021-12-08 National University Corporation Okayama University Reic-expressing adenovirus vector for use in treating cancer
KR101466875B1 (ko) * 2012-05-11 2014-12-03 가톨릭대학교 산학협력단 항종양괴사인자 수용체 2를 발현하도록 설계된 미니서클 벡터를 이용한 자가면역질환 치료
KR101466874B1 (ko) * 2012-05-11 2014-12-03 가톨릭대학교 산학협력단 자가면역 질환의 예방과 치료를 위한 ｉｌ-６ 수용체에 대한 항체를 발현하는 미니서클
US20160287685A1 (en) 2013-11-22 2016-10-06 Amarna Holding B.V. Method for restoring immune tolerance in vivo
EP3090263A4 (en) * 2013-12-31 2017-08-23 Yeda Research and Development Co., Ltd. Methods for assaying immunological competence
US10545144B2 (en) 2013-12-31 2020-01-28 Yeda Research And Development Co., Ltd. Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
CN106535926B (zh) * 2014-06-04 2022-02-01 戴尔米德医疗公司 用于基于抗原的疗法的新型组合物
US12605432B2 (en) 2014-06-04 2026-04-21 Diamyd Medical Ab Combinations for antigen based therapy
EP3265814B1 (en) 2015-03-01 2020-11-18 Immunarray Ltd. Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
WO2017222911A1 (en) * 2016-06-20 2017-12-28 The Board Of Trustees Of The Leland Stanford Junior University Circular rnas and their use in immunomodulation
CA3042321A1 (en) 2016-11-01 2018-05-11 Novo Nordisk A/S Tolerogenic dna vaccine
US20210277417A1 (en) * 2018-06-25 2021-09-09 Akouos, Inc. Methods of treating clrn1-associated hearing loss and/or vision loss
US11279745B2 (en) 2019-04-26 2022-03-22 Novo Nordisk A/S Tolerogenic DNA vaccine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274136B1 (en) * 1996-05-29 2001-08-14 University Of Southern California Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease
WO2000002591A1 (en) * 1998-07-09 2000-01-20 Merck & Co., Inc. Polynucleotide vaccine formulations
WO2000046147A2 (en) * 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US7030098B2 (en) * 1999-03-12 2006-04-18 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for treatment of autoimmune disease
US6479474B2 (en) * 1999-07-08 2002-11-12 Wisconsin Alumni Research Foundation Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
EP1421104A4 (en) * 2001-08-02 2005-08-24 Trinity Biomedical Technology HUMANE ZONA PELLUCIDA PROTEINS AND METHOD FOR THEIR USE IN THE DIAGNOSIS OF MALE INFERENCE
CN101670119A (zh) * 2001-11-21 2010-03-17 利兰·斯坦福青年大学托管委员会 多核苷酸
WO2003082269A1 (en) * 2002-03-29 2003-10-09 The Board Of Trustees Of The Leland Stanford Junior University Use of statins and other immunomodulatory agents in the treatment of autoimmune disease
PT1685251E (pt) * 2003-10-10 2014-04-15 Powderject Vaccines Inc Construções de ácido nucleico

Similar Documents

Publication Publication Date Title
JP2009511014A5 (https=)
Beaton et al. The membrane trafficking protein calpactin forms a complex with bluetongue virus protein NS3 and mediates virus release
Lamm et al. Non-snRNP protein splicing factors
JP6272907B2 (ja) 代謝障害の処置における組成物及び使用方法
Zhang et al. Transcription and identification of an envelope protein gene (p22) from shrimp white spot syndrome virus
JP2020514286A5 (https=)
IL319481A (en) Variants of acid alpha-glucosidase and their uses
JP2017512466A5 (https=)
JP2004024276A (ja) 殺菌／浸透性が向上した安定なタンパク質生成物およびそれを含む薬剤組成物
JP2007297407A5 (https=)
CN114929735A (zh) 因子viii构建体
JP2023535121A5 (https=)
JP2023532917A5 (https=)
JP2009523007A5 (https=)
WO2009031835A4 (en) Cell permeable nm23 recombinant proteins, polynucleotides encoding the same, and anti-metastatic composition comprising the same
CN111718418A (zh) 一种增强基因编辑的融合蛋白及其应用
JP2026034616A (ja) 糖尿病を処置するための修飾型インスリンおよびグルコキナーゼ核酸
Tulalamba et al. Distinct transduction of muscle tissue in mice after systemic delivery of AAVpo1 vectors
Merle et al. Perspectives for gene therapy of Wilson disease
ATE501256T1 (de) Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung
JP2018536432A5 (https=)
CN107073078A (zh) 利用肝细胞生长因子和基质细胞衍生因子1α的用于预防或治疗外周动脉疾病的组合物
JP2020535203A5 (https=)
JP2005512509A5 (https=)
Zelník et al. Structure and properties of a herpesvirus of turkeys recombinant in which US1, US10 and SORF3 genes have been replaced by a lacZ expression cassette